Dapagliflozin

Overview

Dapagliflozin is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) in development for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin is a synthetic C-glucoside compound classified as a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor. Supplied as a stable, crystalline powder, it demonstrates high solubility in organic solvents and notable resistance to enzymatic hydrolysis. By inhibiting SGLT2 in renal proximal tubules, dapagliflozin modulates glucose reabsorption and fosters glycosuric effects, making it a valuable tool in metabolic and renal research. Frequently utilized in studies of glucose homeostasis, cellular transport mechanisms, and metabolic pathway modulation, dapagliflozin supports advanced biochemical investigations.

Application

Products > Drug Discovery > Impurities > Anti-Diabetic > Dapagliflozin and Impurities | Products > Drug Discovery > Inhibitor

Product Information

• Catalog No.: B0084-069214
• CAS No.: 461432-26-8
• Molecular Formula: C21H25ClO6
• Molecular Weight: 408.87
• Purity: >98%
• Storage: Store at -20°C
• Solubility: Soluble in DMSO, Methanol

Source

Original product source